Home  /  Resource Library  /  Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel

Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel

ASH 2020: Study examined rates of hospitalization and additional healthcare resources in patients who received CAR T therapies Tisagenlecleucel and Axicabtagene ciloleucel